Open AccessA serum circulating miRNA diagnostic test to identify asymptomatic high‐risk individuals with early stage lung cancer
Author(s) -
Bianchi Fabrizio,
Nicassio Francesco,
Marzi Matteo,
Belloni Elena,
Dall'Olio Valentina,
Bernard Loris,
Pelosi Giuseppe,
Maisonneuve Patrick,
Veronesi Giulia,
Di Fiore Pier Paolo
Publication year - 2011
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.201100154
Subject(s) - asymptomatic , stage (stratigraphy) , lung cancer , medicine , cancer , disease , population , oncology , clinical significance , lung cancer screening , pathology , biology , paleontology , environmental health
Lung cancer is the first cause of cancer mortality worldwide, and its early detection is currently the main available strategy to improve disease prognosis. While early diagnosis can be successfully achieved through tomography-based population screenings in high-risk individuals, simple methodologies are needed for effective cancer prevention programs. We developed a test, based on the detection of 34 microRNAs (miRNAs) from serum, that could identify patients with early stage non-small cell lung carcinomas (NSCLCs) in a population of asymptomatic high-risk individuals with 80% accuracy. The signature could assign disease probability accurately either in asymptomatic or symptomatic patients, is able to distinguish between benign and malignant lesions, and to capture the onset of the malignant disease in individual patients over time. Thus, our test displays a number of features of clinical relevance that project its utility in programs for the early detection of NSCLC.